Literature DB >> 22010183

Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study.

Yukari Sekiguchi1, Antonino Uncini, Nobuhiro Yuki, Sonoko Misawa, Francesca Notturno, Saiko Nasu, Kazuaki Kanai, Yu-ichi Noto, Yumi Fujimaki, Kazumoto Shibuya, Shigeki Ohmori, Yasunori Sato, Satoshi Kuwabara.   

Abstract

BACKGROUND: Whether or not antiganglioside antibodies are related to axonal or demyelinating Guillain-Barré syndrome (GBS) is still a matter of controversy, as detailed in previous studies conducted in Western and Asian countries.
OBJECTIVE: To clarify whether antiganglioside antibodies are associated with axonal dysfunction in Japanese and Italian GBS patient cohorts.
METHODS: Clinical and electrophysiological profiles were reviewed for 156 GBS patients collected from Japan (n=103) and Italy (n=53). Serum IgG antibodies against GM1, GM1b, GD1a and GalNAc-GD1a were measured by ELISA in the same laboratory. Electrodiagnostic criteria and results of serial electrophysiological studies were used for classification of GBS subtypes: acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN).
RESULTS: In both Japanese and Italian cohorts, any of the antibodies were positive in 36% of the patients, and antibody positivity had a significant association with the AMAN electrodiagnosis. Approximately 30% of Japanese and Italian antiganglioside positive patients showed the AIDP pattern at the first examination whereas sequential studies showed that most finally showed the AMAN pattern. Clinically, seropositive patients more frequently had preceding diarrhoea and pure motor neuropathy in both Japanese and Italian cohorts; vibratory sensation was normal in 97% of Japanese and in 94% of Italian seropositive patients.
CONCLUSIONS: In GBS, clinical and electrophysiological features appear to be determined by antiganglioside antibodies, and the antibodies are associated with motor axonal GBS in both Japan and Italy. Classification of the GBS subtypes as a disease entity should be made, combining the results of antiganglioside assays and serial electrodiagnostic studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22010183     DOI: 10.1136/jnnp-2011-300309

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

Review 1.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

2.  Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes.

Authors:  Nortina Shahrizaila; Norito Kokubun; Setsu Sawai; Thirugnanam Umapathi; Yee-Cheun Chan; Satoshi Kuwabara; Koichi Hirata; Nobuhiro Yuki
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910

3.  [Association of motor nerve conduction block with different subtypes of childhood Guillain-Barré syndrome].

Authors:  Rui-Di Sun; Jun Jiang; Zhi-Sheng Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-09

4.  An electrophysiological classification associated with Guillain-Barré syndrome outcomes.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

Review 5.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

6.  Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barré syndrome in Korea: a nationwide multicenter study.

Authors:  Jong Kuk Kim; Jong Seok Bae; Dae-Seong Kim; Susumu Kusunoki; Jong Eun Kim; Ji Soo Kim; Young-Eun Park; Ki-Jong Park; Hyun Seok Song; Sun Young Kim; Jeong-Geun Lim; Nam-Hee Kim; Bum Chun Suh; Tai-Seung Nam; Min Su Park; Young-Chul Choi; Eun Hee Sohn; Sang-Jun Na; So Young Huh; Ohyun Kwon; Su-Yun Lee; Sung-Hoon Lee; Sun-Young Oh; Seong-Hae Jeong; Tae-Kyeong Lee; Dong Uk Kim
Journal:  J Clin Neurol       Date:  2014-04-23       Impact factor: 3.077

Review 7.  Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis.

Authors:  Lina Palaiodimou; Maria-Ioanna Stefanou; Aristeidis H Katsanos; Paraskevi C Fragkou; Marianna Papadopoulou; Christos Moschovos; Ioannis Michopoulos; Panagiotis Kokotis; Christos Bakirtzis; Androniki Naska; Theodoros I Vassilakopoulos; Elisabeth Chroni; Sotirios Tsiodras; Georgios Tsivgoulis
Journal:  Eur J Neurol       Date:  2021-04-28       Impact factor: 6.288

Review 8.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

9.  Association between human leukocyte antigen-DR and demylinating Guillain-Barre syndrome.

Authors:  Zaki N Hasan; Haider H Zalzala; Hyam R Mohammedsalih; Batool M Mahdi; Laheeb A Abid; Zena N Shakir; Maithem J Fadhel
Journal:  Neurosciences (Riyadh)       Date:  2014-10       Impact factor: 0.906

Review 10.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.